Ingredients for success
State-of-the-art technology is used to efficiently create quality products.
Quality production is essential when it comes to active pharmaceutical ingredients. Years of specialisation combined with a dedicated workforce and the use of cutting-edge technologies go a long way to maintaining the high standards required by clients.
Teva Active Pharmaceutical Ingredients (TAPI) is a business unit of Teva Pharmaceutical Industries Limited. With more than 70 years’ experience it has become a leading international supplier of active pharmaceutical ingredients to generic and innovative companies, with over $1.4 billion in annual sales. Employing over 4,000 professionals worldwide, TAPI offers a rich portfolio of over 260 active pharmaceutical ingredients.
Through decades of specialisation in the production of API, TAPI has gained unparalleled expertise in custom synthesis. It offers professional services that marry the science of chemistry with the company’s vast experience in process development, yielding efficient, high quality production.
Research and development (R&D) is performed by a dedicated team of over
500 top scientists. This diverse team is located
in six development
centres throughout the world, specialising in
the following fields:
- Chemical synthesis
- High potency
- Plant extract
- Synthetic peptides
- Vitamin D derivatives
- Analytical and solid
By contracting TAPI for custom synthesis services, clients engage the knowledge and abilities
of the company’s top scientists who are renowned for their expertise in
the development of manufacturing processes and technologies, as well as their experience in applying this expertise to synthesis. Given the specifications
of lab molecules, these scientists create practical, efficient plans for bringing the material quickly
TAPI offers unique abilities in the following areas:
- Highly potent drugs
- Vitamin D derivatives
Knowledge and flexibility
Since 1988, a fermentation and downstream plant, especially built for highly potent drugs, has been exclusively producing anti-cancer drugs, thereby exhibiting TAPI’s leadership in developing and improving strains for
APIs by fermentation.
Over the last 15 years TAPI has developed its expertise in the development and commercialisation of peptide APIs. It offers production capabilities from grammes to hundreds of kilogrammes, a comprehensive technology platform including solid phase, solution phase and
a hybrid approach, combined with well established scientific experience. These capabilities enable the efficient production of
a high quality product.
It is also one of the principal developers
and producers of vitamin D derivatives and has large production capacities.
TAPI offers the best outsourced solution for achieving high quality, highly efficient pharmaceutical manufacturing. Its
global production capacity enables it to offer flexibility in delivering the quantities required, whenever they
Decades of experience
in the research and implementation of production techniques
have given TAPI distinctive advantages that clients
can leverage to benefit
their bottom line, without risking a commitment
TAPI enjoys an international presence in the healthcare industry. With its headquarters based in Israel, 80% of its sales are generated in Europe and North America. It has facilities in Israel, North America, Latin America and Europe. For more information, visit: www.teva.co.il